Table 3 Pre-treatment demographics, headache and migraine frequency, scores on ASC-12, MIDAS, BDI, and temperatures required to elicit moderate intensity pain. Medication overuse refers to participants who were using abortive medications more often than the thresholds defined for medication overuse by the ICHD-3 diagnostic criteria. Concurrent migraine preventive medication refers to the percentage of participants who were using migraine preventive medications in addition to erenumab. There were no differences in these pre-treatment values between participants who became erenumab responders vs. erenumab non-responders except that a larger proportion of participants who became erenumab responders were using concurrent migraine preventive medications. ASC-12 = Allodynia Symptom Checklist 12; MIDAS = Migraine Disability Assessment; BDI = Beck Depression Inventory
|  | All Participants (n = 32) | Erenumab Responders (n = 18) | Erenumab Non-Responders (n = 14) | p-value (responders vs. non-responders) |
|---|---|---|---|---|
Age, mean (SD) | 40.3 (13) | 41.9 (13) | 38.3 (13) | 0.45 |
Female, percentage | 91% | 89% | 93% | 0.99 |
Headache Day Frequency/ 28 days, mean (SD) | 15.8 (4.4) | 15.8 (4.8) | 15.7 (3.9) | 0.96 |
Migraine Day Frequency/ 28 days, mean (SD) | 13.8 (4.7) | 14.8 (5.1) | 12.6 (4.2) | 0.20 |
Years with Migraine, mean (SD) | 21.9 (12.4) | 22.6 (12.9) | 20.8 (12.2) | 0.70 |
Medication Overuse, percentage | 59.4% | 66.7% | 50% | 0.47 |
Concurrent Migraine Preventive Medication, percentage | 31.3% | 55.6% | 0% | .001 |
ASC-12 scores, mean (SD) | 4.7 (3.1) | 4.5 (3.1) | 4.9 (3.2) | 0.70 |
Thermode Temperature Causing Moderate Pain, mean (SD), 0C | 45.8 (2.4) | 46.0 (2.8) | 45.6 (1.8) | 0.63 |
MIDAS scores, mean (SD) | 35.9 (27) | 38 (31) | 33 (21) | 0.61 |
BDI scores, mean (SD) | 5.8 (4.8) | 5.6 (4.3) | 6.1 (5.6) | 0.80 |